OpGen is in the medical diagnostics and research industry and trades as part of the healthcare sector. The company CEO is Evan Jones. OpGen Inc is an precision medicine company using molecular diagnostics and bioinformatics to help combat infectious disease.

Previous Intraday Performance:

The OPGN shares had a previous change of -4.08% which opened at 0.58 and closed at 0.56. It moved to an intraday high of 0.60 and a low of 0.56.

SeekingAlpha:  OpGen announces closing of public offering of common stock

Historical Performance:

Over the last five trading days, OPGN shares returned -6.65% and in the past 30 trading days it returned -53.65%. Over three months, it changed -66.86%. In one year it has changed -72.95% and within that year its 52-week high was 2.90 and its 52-week low was 0.53. OPGN stock is 5.66% above its 52 Week Low.

Our calculations result in a 200 day moving average of 1.49 and a 50 day moving average of 1.06. Right now, OPGN stock is trading -62.36% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  OpGen announces closing of public offering of common stock


The company has a market cap of $9.9m with 17.6m shares outstanding and a float of 17.4m shares. Trading volume was 183,037 shares and has experienced an average volume of 487,289 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for OpGen was -2.27 which ended on 31st of December 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.33.

The next earnings report will be: 05-09-2019

The growth of the EPS is critical in understanding the current valuation of OpGen; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -76.00% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 4.70% of institutional ownership.

I calculated the beta to be 1.04

SeekingAlpha:  Tracking Chase Coleman’s Tiger Global Portfolio – Q4 2018 Update

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -574.99%, return on assets is -174.89%, price-to-sales is 4.91 and price-to-book is 3.11.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 3  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here